Role of calcium and vitamin d in prevention of postmenopausal osteoporosis in patients with endometriosis

In: Reproductive Endocrinology · 2015 · vol. 0(22) , pp. 70 · doi:10.18370/2309-4117.2015.22.70-75 · W1851987416
article OA: diamond CC0
AI-generated summary by claude@2026-06, 2026-06-08

Calcium-D3 Nycomed slowed or stopped bone loss in postmenopausal women with endometriosis and calcium deficiency, suggesting its use for osteopenia prevention.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The study to assess the effectiveness of the use of the drug Calcium-D3 Nycomed for the prevention and correction of disorders of calcium-phosphorus metabolism, bone metabolism in 67 patients with endometriosis on the background of climacteric syndrome and calcium deficiency was performed. 35 patients (main group) against the symptomatic treatment of climacteric syndrome were prescribed Calcium-D3 Nycomed. 32 patients, who did not receive calcium supplements, entered the control group. The period of observation in the course of treatment was 3 months.The most important result of the treatment was slowing or stopping bone loss resulting from the use of Calcium-Dз Nycomed. It is possible to recommend the use of this drug in patients with endometriosis and symptoms of hypocalcemia on the background of climacteric syndrome for the prevention and treatment of osteopenic syndrome

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

References (7)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK